Journals / Marmara Medical Journal / 2007 / Cilt: 20 - Sayı: 2

Lenfomalı hastalarda kemoterapinin yaşam kalitesine etkisi

Effect of chemotherapy on quality of life in patients with lymphoma

Pages
98–103
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results may be used to reassure the patients who are reluctant to go through chemotherapy that they are likely to experience an improved quality of life compared to their situation before the treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Advances in chemotherapy have significantly prolonged survival of patients with lymphoma and a significant percentage of patients may be cured.
📊
Key Findings & Data:Methods: All patients (n=49) diagnosed with stage I lymphoma in the Cukurova University Oncology Department from June 2000 to January 2001 received a quality-of-life questionnaire (EORTC QLQ C-30) before chemotherapy and after the second cycle of chemotherapy.
💡
Conclusion & Impact:Conclusion: The results may be used to reassure the patients who are reluctant to go through chemotherapy that they are likely to experience an improved quality of life compared to their situation before the treatment.
🔬Design:Survey & Empirical Study
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Advances in chemotherapy have significantly prolonged survival of patients with lymphoma and a significant percentage of patients may be cured. The assessment of the quality of life in patients undergoing chemotherapy is of growing interest. The aim of this study is to assess the effect of chemotherapy on quality of life in patients with lymphoma. Methods: All patients (n=49) diagnosed with stage I lymphoma in the Cukurova University Oncology Department from June 2000 to January 2001 received a quality-of-life questionnaire (EORTC QLQ C-30) before chemotherapy and after the second cycle of chemotherapy. Results: Significant improvement during treatment was found in some of the physical activities, emotional functioning, relieve from pain and fatigue, dyspnea, anorexia, sleep, and global quality of life. When chemotherapy, age, gender and lymphoma type were taken into account, the most important factor influencing the global quality of life was educational status. Conclusion: The results may be used to reassure the patients who are reluctant to go through chemotherapy that they are likely to experience an improved quality of life compared to their situation before the treatment.

Özet

Amaç: Kemoterapideki gelişmeler lenfomalı hastaların yaşam sürelerini önemli derecede uzatmıştır ve önemli sayıda hasta tedavi edilebilmektedir. Kemoterapi alan hastaların yaşam kalitelerinin değerlendirilmesi giderek daha fazla ilgi çeken bir konu olmuştur. Çalışmamızın amacı, lenfomalı hastalarda kemoterapinin yaşam kalitesine etkilerini değerlendirmektir. Gereç ve Yöntem: Haziran 2000-Ocak 2001 tarihleri arasında Çukurova Üniversitesi Tıp Fakültesi Onkoloji Bilim Dalı’nda Evre I lenfoma tanısı alan 49 hastaya kemoterapi öncesinde ve 2. kür sonrasında yaşam kalitesi anketi (EORTC QLQ C-30) uygulandı. Bulgular: Fiziksel aktivitelerin bazılarında, duygusal fonksiyonlar, ağrı ve halsizlik, dispne, iştahsızlık, uyku ve global yaşam kalitesinde tedavi sırasında anlamlı iyileşme saptandı. Kemoterapi, yaş, cinsiyet ve lenfoma tipi göz önüne alındığında, global yaşam kalitesini etkileyen en önemli faktör hastanın eğitim durumuydu. Sonuç: Çalışmamızın sonuçları, kemoterapi öncesindeki yaşam kalitesine kıyasla tedavi sonrası yaşam kalitesinde iyileşme olması nedeniyle, kemoterapi alma konusunda isteksiz olan hastalara yardımcı olmada kullanılabilir.

🔖

Cite This Article

SAATÇİ, E., KOÇAK, Y., BOZDEMİR, N., AKPINAR, E., KALAYLIOĞLU-WHEELER, Z. (2007). Lenfomalı hastalarda kemoterapinin yaşam kalitesine etkisi. Marmara Medical Journal, Cilt: 20 - Sayı: 2, 98–103. https://ajindex.com/articles/284198

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Guyatt G, Veldhuyzen Van Zanten S, Feeny D, Patrick D. Measuring quality of life in clinical trials: a taxonomy and review. Can Med Assoc J 1989; 140: 1441-1448
  2. Lauper P, Versteegen U. The importance of quality of life in policy decisions: new end points in medical outcome assessment. Pharm Med 1992; 5: 43-50
  3. Schumacher A, Kessler T, Riedel A, Buchner T, van de Loo J. Quality of life and coping with illness in patients with acute myeloid leukemia. Psychother Psychosom Med Psychol 1996; 46: 385-390
  4. Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Medical Oncology 2001; 18: 85-94
  5. Persson L, Larsson G, Ohlsson O, Hallberg IR. Acute leukemia or highly malignant lymphoma patients’ quality of life over two years: a pilot study. Eur J of Cancer Care 2001; 10: 36-47
  6. Cella DF, Tulsky S. Measuring quality of life today: methodological aspects. Oncology 1990; 4: 29-38
  7. The WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403-1409
  8. Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson BD. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 1992; 84: 575-579
  9. Cella DF. Quality of life: the concept. J Palliat Care 1992; 8: 8-13
  10. Kaasa S, Loge JH. Quality of life in palliative care: principles and practice. Palliat Med 2003; 17: 11-20
  11. Wierzbicka M, Kusnierkiewicz M, Wojtowicz JG, Maune S, Szyfter W. The quality of life in head and neck cancer patients: description of randomized examination formula based on standardized questionnaires EORTC QLQ C-30, EORTC QTQ-H-N35 and Kiel Questionnaire. Otolaryngol Pol 2001; 55: 287-292 [in Polish]
  12. Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analyzed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260-2263
  13. Kobayashi K, Takeda F, Teramukai S, Gotah I, Sakai H, Yoneda S et al. A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 1998; 34: 810–815
  14. Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A. Modification of the EORTC QLQ-C30 (versio